Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| astrocyte | 14 studies | 35% ± 17% | |
| oligodendrocyte | 12 studies | 36% ± 13% | |
| endothelial cell | 12 studies | 31% ± 12% | |
| microglial cell | 11 studies | 30% ± 13% | |
| glutamatergic neuron | 10 studies | 40% ± 24% | |
| oligodendrocyte precursor cell | 10 studies | 35% ± 15% | |
| fibroblast | 10 studies | 29% ± 13% | |
| GABAergic neuron | 9 studies | 44% ± 21% | |
| macrophage | 8 studies | 28% ± 13% | |
| epithelial cell | 8 studies | 29% ± 13% | |
| adipocyte | 7 studies | 32% ± 8% | |
| neuron | 6 studies | 37% ± 17% | |
| interneuron | 6 studies | 49% ± 23% | |
| retinal cone cell | 6 studies | 32% ± 16% | |
| kidney loop of Henle epithelial cell | 5 studies | 28% ± 6% | |
| retina horizontal cell | 5 studies | 34% ± 15% | |
| cardiac muscle cell | 5 studies | 31% ± 8% | |
| smooth muscle cell | 5 studies | 23% ± 4% | |
| basal cell | 5 studies | 30% ± 15% | |
| epithelial cell of proximal tubule | 4 studies | 20% ± 5% | |
| granule cell | 4 studies | 30% ± 6% | |
| retinal ganglion cell | 4 studies | 31% ± 12% | |
| ciliated cell | 4 studies | 21% ± 7% | |
| retinal rod cell | 4 studies | 39% ± 10% | |
| club cell | 4 studies | 27% ± 9% | |
| endothelial cell of lymphatic vessel | 4 studies | 30% ± 8% | |
| pericyte | 4 studies | 25% ± 6% | |
| type I pneumocyte | 4 studies | 22% ± 8% | |
| type II pneumocyte | 4 studies | 21% ± 7% | |
| GABAergic interneuron | 3 studies | 37% ± 5% | |
| plasma cell | 3 studies | 24% ± 4% | |
| GABAergic amacrine cell | 3 studies | 28% ± 14% | |
| amacrine cell | 3 studies | 33% ± 21% | |
| glycinergic amacrine cell | 3 studies | 30% ± 11% | |
| hepatocyte | 3 studies | 48% ± 21% | |
| ependymal cell | 3 studies | 33% ± 13% | |
| natural killer cell | 3 studies | 22% ± 2% | |
| lymphocyte | 3 studies | 27% ± 11% | |
| mast cell | 3 studies | 20% ± 3% | |
| kidney distal convoluted tubule epithelial cell | 3 studies | 28% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 755.76 | 1445 / 1445 | 100% | 15.28 | 183 / 183 |
| intestine | 100% | 1102.03 | 966 / 966 | 100% | 21.77 | 527 / 527 |
| prostate | 100% | 1511.37 | 245 / 245 | 100% | 65.47 | 502 / 502 |
| stomach | 100% | 1223.03 | 359 / 359 | 100% | 18.91 | 286 / 286 |
| kidney | 100% | 2491.84 | 89 / 89 | 100% | 39.94 | 898 / 901 |
| brain | 100% | 1156.67 | 2634 / 2642 | 100% | 16.72 | 704 / 705 |
| thymus | 100% | 1356.99 | 653 / 653 | 99% | 36.94 | 601 / 605 |
| liver | 100% | 824.41 | 226 / 226 | 99% | 20.01 | 403 / 406 |
| adrenal gland | 100% | 3077.62 | 258 / 258 | 99% | 32.37 | 228 / 230 |
| breast | 100% | 1182.04 | 459 / 459 | 99% | 21.28 | 1108 / 1118 |
| pancreas | 100% | 755.44 | 328 / 328 | 99% | 19.23 | 176 / 178 |
| lung | 100% | 833.26 | 576 / 578 | 99% | 15.85 | 1146 / 1155 |
| ovary | 100% | 976.73 | 180 / 180 | 98% | 16.55 | 423 / 430 |
| uterus | 100% | 933.80 | 170 / 170 | 97% | 15.54 | 446 / 459 |
| bladder | 100% | 783.43 | 21 / 21 | 96% | 15.45 | 483 / 504 |
| skin | 100% | 748.76 | 1807 / 1809 | 88% | 11.51 | 414 / 472 |
| adipose | 100% | 1024.16 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 100% | 665.30 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 7.36 | 1 / 1 |
| muscle | 100% | 831.03 | 801 / 803 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 722.80 | 1330 / 1335 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 98% | 15.33 | 44 / 45 |
| heart | 98% | 1256.58 | 841 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 86% | 14.54 | 25 / 29 |
| eye | 0% | 0 | 0 / 0 | 79% | 12.36 | 63 / 80 |
| peripheral blood | 71% | 249.53 | 661 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006635 | Biological process | fatty acid beta-oxidation |
| GO_0006552 | Biological process | L-leucine catabolic process |
| GO_0005759 | Cellular component | mitochondrial matrix |
| GO_0005739 | Cellular component | mitochondrion |
| GO_0050011 | Molecular function | itaconyl-CoA hydratase activity |
| GO_0004490 | Molecular function | methylglutaconyl-CoA hydratase activity |
| GO_0004300 | Molecular function | enoyl-CoA hydratase activity |
| GO_0003730 | Molecular function | mRNA 3'-UTR binding |
| Gene name | AUH |
| Protein name | Methylglutaconyl-CoA hydratase, mitochondrial (3-MG-CoA hydratase) (EC 4.2.1.18) (AU-specific RNA-binding enoyl-CoA hydratase) (AU-binding protein/enoyl-CoA hydratase) (Itaconyl-CoA hydratase) (EC 4.2.1.56) |
| Synonyms | |
| Description | FUNCTION: Catalyzes the fifth step in the leucine degradation pathway, the reversible hydration of 3-methylglutaconyl-CoA (3-MG-CoA) to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) . Can catalyze the reverse reaction but at a much lower rate in vitro . HMG-CoA is then quickly degraded by another enzyme (such as HMG-CoA lyase) to give acetyl-CoA and acetoacetate . Uses other substrates such as (2E)-glutaconyl-CoA efficiently in vitro, and to a lesser extent 3-methylcrotonyl-CoA (3-methyl-(2E)-butenoyl-CoA), crotonyl-CoA ((2E)-butenoyl-CoA) and 3-hydroxybutanoyl-CoA (the missing carboxylate reduces affinity to the active site) . Originally it was identified as an RNA-binding protein as it binds to AU-rich elements (AREs) in vitro . AREs direct rapid RNA degradation and mRNA deadenylation . Might have itaconyl-CoA hydratase activity, converting itaconyl-CoA into citramalyl-CoA in the C5-dicarboxylate catabolism pathway . The C5-dicarboxylate catabolism pathway is required to detoxify itaconate, an antimicrobial metabolite and immunomodulator produced by macrophages during certain infections, that can act as a vitamin B12-poisoning metabolite . . |
| Accessions | Q13825 ENST00000303617.5 [Q13825-2] ENST00000375731.9 [Q13825-1] |